89bio Will Present 48-Week Data From ENLIVEN Phase 2b Pegozafermin Trial In MASH At EASL International Liver Congress

5/22/24 4:22:47 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ETNB alert in real time by email

89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that data from the 48-week extension phase of the Phase 2b ENLIVEN trial evaluating pegozafermin in patients with metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis will be presented in an oral and poster presentation at the European Association for the Study of the Liver (EASL) Congress to be held June 5 to 8, 2024 in Milan, Italy.

Get the next $ETNB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ETNB

Date	Price Target	Rating	Analyst
4/22/2024	$30.00	Buy	BofA Securities
1/12/2024	$24.00 → $15.00	Outperform → Sector Perform	RBC Capital Mkts
10/10/2023		Outperform → Perform	Oppenheimer
8/28/2023	$36.00	Buy	UBS
6/13/2023	$49.00	Outperform	Evercore ISI
5/12/2022	$33.00 → $12.00	Outperform → Strong Buy	Raymond James
12/20/2021	$46.00	Buy	HC Wainwright & Co.
10/26/2021	$58.00 → $49.00	Overweight	Cantor Fitzgerald

More analyst ratings

$ETNB
Financials

Live finance-specific insights

89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
- 44mg Q2W dose had a placebo-adjusted effect size of 20% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 24% on NASH resolution without worsening of fibrosis (p=0.0005) - - 30mg QW dose had a placebo-adjusted effect size of 19% on at least one-stage fibrosis improvement without worsening of NASH (p=0.008) and 21% on NASH resolution without worsening of fibrosis (p=0.0009) - - 44mg Q2W and 30mg QW doses had at least one-stage fibrosis improvement without worsening of NASH at 3.5 times placebo rate and NASH resolution without worsening of fibrosis at 12 to 14 times placebo rate - - Every-two-week dose data reinforces pegozafermin's pot
3/22/23 7:00:00 AM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)
- Trial met primary endpoint demonstrating statistically significant and clinically meaningful reductions across all doses (63% at the 27mg QW dose; p<0.001) in triglycerides (TG) from baseline; results were consistent in patients on or not on background therapy - - Observed significant and potent reductions in atherogenic lipids (non-HDL-C and apo B), liver fat, and improvements in liver enzymes and glycemic control markers - - ENTRIGUE results support 89bio's transition to a late-stage development company; Phase 3 expected to initiate in first half of 2023 - - Conference call and webcast today at 1:30 p.m. PST/4:30 p.m. EST - SAN FRANCISCO, June 28, 2022 (GLOBE NEWSWIRE) -- 89bio, In
6/28/22 4:01:00 PM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
- Interim data from NL-201 Phase 1 trial for patients with relapsed and refractory solid tumors anticipated in the second half of 2022 – - $142.5 million in cash and cash equivalents expected to provide runway into the second half of 2023 – - Appointment of Rohan Palekar to Board of Directors – - Company to host conference call today, March 1, 2022 at 1:30 p.m. PT / 4:30 p.m. ET – SEATTLE, March 01, 2022 (GLOBE NEWSWIRE) -- Neoleukin Therapeutics, Inc., "Neoleukin" (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended December 31, 2021.
3/1/22 4:03:00 PM ET
$ETNB
$NLTX
Biotechnology: Pharmaceutical Preparations
Health Care

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer
SAN FRANCISCO, Sept. 16, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced the appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer, effective today. Dr. Perney brings an extensive track record of expertise and leadership in Regulatory, Product Development and Quality in the industry to the Company. "We are delighted to welcome Dr. Teresa Perney to our executive leadership team at this critical juncture for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance pegozafermin through
9/16/24 4:05:00 PM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
89bio Appoints Francis Sarena as Chief Operating Officer
SAN FRANCISCO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Francis Sarena as Chief Operating Officer, effective August 5, 2024. "We are excited to welcome Francis to our executive team at this pivotal growth phase for 89bio," said Rohan Palekar, CEO of 89bio. "As we advance our Phase 3 clinical program for pegozafermin and prepare for scale up, Francis' extensive strategic, operational, business development and leadership expertise will be immensely valuable. His prov
8/7/24 8:00:00 AM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
89bio Appoints Charles McWherter, Ph.D., to its Board of Directors
SAN FRANCISCO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the appointment of Dr. Charles McWherter to its Board of Directors, effective July 30, 2024. Dr. McWherter most recently served as Chief Scientific Officer and President of Research and Development of CymaBay Therapeutics until it was acquired by Gilead Sciences in March 2024. "We are thrilled to welcome Charles, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, CEO of 89bio. "His expertise in drug dev
8/5/24 8:00:00 AM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care

$ETNB
Press Releases

Fastest customizable press release news feed in the world

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024
SAN FRANCISCO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, announced new analyses of data from the Phase 2b ENLIVEN trial evaluating pegozafermin in metabolic dysfunction-associated steatohepatitis (MASH) patients with advanced fibrosis. The findings were presented in four poster sessions at The American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® being held in San Diego, California. "We are excited to present additional analyses from our Phase 2b ENLIVEN trial at this year'
11/15/24 8:05:00 AM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced the pricing of its previously announced upsized underwritten public offering of 11,455,882 shares of its common stock at a public offering price per share of $8.50 and, in lieu of common stock to a certain investor, pre-funded warrants to purchase up to 3,250,000 shares of its common stock at a public offering price of $8.499. The pre-funded warrants have an exercise price of $0.001 per share and are exercisable immedia
11/12/24 11:58:01 PM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care
89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants
SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- 89bio, Inc. ("89bio") (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that it has commenced an underwritten public offering of $100 million of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. In addition, 89bio is expected to grant the underwriters of the offering an option for a period of 30 days to purchase up to an additional $15 million of shares of its common stock at the public off
11/12/24 4:01:31 PM ET
$ETNB
Biotechnology: Pharmaceutical Preparations
Health Care

89bio Will Present 48-Week Data From ENLIVEN Phase 2b Pegozafermin Trial In MASH At EASL International Liver Congress

Chat with this insight

Recent Analyst Ratings for $ETNB

$ETNB Financials

Live finance-specific insights

89bio's Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks

89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG)

Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update

$ETNB Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

SEC Form 4 filed by Director Ra Capital Management, L.P.

Officer Le-Nguyen Quoc sold $226,995 worth of shares (27,955 units at $8.12), decreasing direct ownership by 13% to 187,796 units (SEC Form 4)

Chief Financial Officer Martins Ryan covered exercise/tax liability with 3,212 shares, decreasing direct ownership by 3% to 102,620 units (SEC Form 4)

$ETNB Large Ownership Changes

This live feed shows all institutional transactions in real time.

Amendment: SEC Form SC 13D/A filed by 89bio Inc.

Amendment: SEC Form SC 13G/A filed by 89bio Inc.

Amendment: SEC Form SC 13G/A filed by 89bio Inc.

$ETNB SEC Filings

SEC Form 8-K filed by 89bio Inc.

SEC Form 424B5 filed by 89bio Inc.

SEC Form 424B5 filed by 89bio Inc.

$ETNB Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$ETNB Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Ra Capital Management, L.P. bought $20,722,500 worth of shares (1,350,000 units at $15.35) (SEC Form 4)

BofA Securities resumed coverage on 89bio with a new price target

89bio downgraded by RBC Capital Mkts with a new price target

89bio downgraded by Oppenheimer

$ETNB Market Insights

Live Market Insights

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

Cantor Fitzgerald Reiterates Overweight on 89bio, Maintains $29 Price Target

$ETNB Leadership Updates

Live Leadership Updates

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

89bio Appoints Francis Sarena as Chief Operating Officer

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

$ETNB Press Releases

Fastest customizable press release news feed in the world

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

Recent Analyst Ratings for
$ETNB

$ETNB
Financials

$ETNB
Insider Trading

$ETNB
Large Ownership Changes

$ETNB
SEC Filings

$ETNB
Insider Purchases

$ETNB
Analyst Ratings

$ETNB
Market Insights

$ETNB
Leadership Updates

$ETNB
Press Releases